Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AryoGen denosumab versus Xgeva in breast cancer with bone metastasis
IRCT20150303021315N21Phase 3Completed
- Sponsor
- AryoGen Biopharma
- Start
- Feb 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of denosumab in breast cancer (2 arms), sponsored by AryoGen Biopharma. Primary endpoint: Time to first on-study skeletal-related event. Started Feb 2021; status: completed.
02
Drugs
denosumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on IRCT20150303021315N21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20150303021315N21.